vip

[D-p-Cl-Phe6,Leu17]-VIP acetate is a competitive and selective antagonist of vasoactive intestinal peptide (VIP) receptor (IC50 = 125.8 nM).

VIP(6-28)(human, rat, porcine, bovine) acetate is an antagonist of the actions of exogenous vasoactive intestinal peptide (VIP) receptor on cAMP in the superior cervical ganglion (SCG).

Prepro VIP (111-122), human acetate is a prepro-vasoactive intestinal polypeptide (VIP)–derived peptide, corresponding to residues 111-122.

[D-p-Cl-Phe6,Leu17]-VIP TFA acts as a competitive and selective antagonist of the vasoactive intestinal peptide (VIP) receptor, with an IC50 of 125.8 nM, and shows no activity on glucagon, secretin, or growth hormone-releasing factor (GRF) receptors [1] [2] [3].

[K15,R16,L27]VIP(1-7) GRF(8-27) (acetate) is an acetate salt form of the peptide [K15,R16,L27]VIP(1-7) GRF(8-27), acting as a selective agonist for the VIP 1 receptor with IC50 values of 2 nM for human VIP 1, 1 nM for rat VIP 1, and 30,000 nM for rat VIP 2 receptors. The peptide's acronym, VIP, stands for Vasoactive Intestinal Polypeptide.

Vasoactive Intestinal Peptide (VIP) Guinea pig TFA, a trophic and mitogenic factor, promotes growth in cultured whole embryos and acts as a gastrointestinal hormone, while also indicating potential neurotransmitter functions [1] [2].

Myristoyl-(Lys12,27,28)-VIP-Gly-Gly-Thr (free acid) acts as a selective and potent antagonist of the VPAC2 receptor [1].

Acetyl-(D-Phe2,Lys15,Arg16,Leu27)-VIP(1-7)-GRF(8-27) is a selective antagonist for the vasoactive intestinal peptide 1 (VIP 1) receptor.

[K15,R16,L27]VIP(1-7) GRF(8-27), a selective agonist for the VIP 1 receptor, demonstrates binding IC50 values of 2 nM for the human VIP 1, 1 nM for the rat VIP 1, and 30,000 nM for the rat VIP 2 receptors, respectively [1]. VIP stands for VASOACTIVE Intestinal Polypeptide.

VIP(6-28)(human, rat, porcine, bovine) is a potent antagonist that counteracts the effects of exogenous vasoactive intestinal peptide (VIP) on cyclic adenosine monophosphate (cAMP) signaling.

Prepro VIP (111-122), human, is a peptide derived from prepro-vasoactive intestinal polypeptide (VIP), corresponding to residues 111-122.

Prepro VIP (81-122), human, is a peptide derived from prepro-vasoactive intestinal polypeptide (VIP), corresponding to residues 81-122.

Selective vasoactive intestinal peptide (VIP) receptor antagonist (IC50 = 125.8 nM). Displays no activity on glucagon, secretin or GRF receptors.

Neuropeptide with many biological actions

VIPhyb is a vasoactive intestinal polypeptide (VIP) receptor antagonist utilized for research in various cancers, including non-small cell lung cancer (NSCLC) [1].

Aviptadil (INN) is an analog of vasoactive intestinal polypeptide (VIP) for the treatment of erectile dysfunction.

Aviptadil Acetate (Vasoactive Intestinal Peptide acetate salt) induces pulmonary vasodilation and inhibits the proliferation of vascular SMCs and platelet aggregation. Avitadil acetate can be used for research on pulmonary fibrosis, pulmonary hypertension (PAH), and respiratory failure caused by SARS-CoV-2.

PACAP-related peptide (PRP) is an endogenous 29-amino acid peptide that belongs to the secretin/glucagon superfamily of peptides, which includes secretin , glucagon , glucagon-like peptide-1 , GLP-2 , and pituitary adenylate cyclase-activating polypeptide . It is expressed in normal human pancreas and adrenal gland tissue and in some tumors that produce vasoactive intestinal peptide (VIP). PRP (1-29) is secreted by CHO-K1 cells that express human recombinant preproPACAP.

[Ac-Tyr1,D-Phe2]GRF 1-29, amide (human) is an analog of GRF and a vasoactive intestinal peptide (VIP) antagonist.

PACAP (6-27) (human, ovine, rat) is an antagonist for the PACAP receptor, inhibiting the catecholamine response of the canine adrenal gland to vasoactive intestinal peptide (VIP), making it a valuable compound for research into cardiovascular and neurological disorders [1].

Vasomera, a stable, long-acting vasoactive intestinal peptide (VIP) agonist, targets G-protein-coupled VPAC2 receptors and is employed in the study of cardiomyopathy associated with dystrophinopathies [1].

Helospectin II, a member of the vasoactive intestinal peptide (VIP) family, exhibits vasodilatory and antihypertensive properties that reduce blood pressure. This neuropeptide was initially isolated from the venom of the salivary glands of the Heloderma suspectum lizard [1] [2].

Helospectin I, a neuropeptide belonging to the vasoactive intestinal peptide (VIP) family, exhibits vasodilatory and antihypertensive properties, effectively reducing blood pressure. It was initially isolated from the salivary gland venom of the lizard Heloderma suspectum [1] [2].

PACAP (1-38), a novel neuropeptide isolated from the bovine hypothalamus is more active than vasoactive intestinal peptide (VIP) in stimulating adenylate cyclase (EC50=7 nM). PACAP 1-38 (10-9 M) increased substance P (SP), gastrin releasing peptide (GRP),